ArticleEuropean journal of medical research2025
Exploration of purine metabolism-related genes in the development of osteoporosis by integrated analyses and experiments.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveMetabolomics analyses suggest abnormal purine metabolism during the development of osteoporosis. This study aimed to investigate the role of purine metabolism-related genes in osteoporosis.
methodsThree microarray datasets for osteoporosis were used in this study. Purine metabolism activity score was quantified by GSVA. Differential expression analysis and weighted Gene Co-expression Network Analysis (WGCNA) were employed to screen dysregulated purine metabolism activity-related genes in osteoporosis. Three machine learning algorithms were employed to screen potential biomarkers, and a predictive nomogram based on biomarkers was then established. Drugs that target the biomarkers were predicted based on the DGIDB database. An ovariectomized rat model causing osteoporosis was established to validate the expression of biomarkers and the purine metabolism in vivo.
resultsPurine metabolism activity of osteoporosis samples was significantly different from controls. Based on differential analysis and WGCNA, 122 dysregulated purine metabolism-related genes were found, and they were mainly involved in immune inflammation-related functions. PDPK1 and FOXO3 were identified as potential biomarkers, and the nomogram based on PDPK1 and FOXO3 showed well performance to predict the onset risk of osteoporosis, with a clinical net benefit greater than PDPK1 and FOXO3 each alone. Two approved drugs, resveratrol and celecoxib, were predicted to target FOXO3 and PDPK1, respectively. Expression of FOXO3 and PDPK1 was enhanced in osteoporosis both in bioinformatics analysis and in vivo experiments. Rat model showed higher serum levels of xanthine and hypoxanthine as well as high level of uric acid.
conclusionFOXO3 and PDPK1 might be biomarkers and targets for the prevention and treatment of osteoporosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.